PURPOSE: Little is known about the trajectory of post-traumatic stress disorder (PTSD) symptoms in cancer survivors, despite the fact that such knowledge can guide treatment. Therefore, this study examined changes in PTSD symptoms among long-term survivors of non-Hodgkin's lymphoma (NHL) and identified demographic, clinical, and psychosocial predictors and correlates of PTSD symptomatology. PATIENTS AND METHODS: Surveys were mailed to 682 NHL survivors who participated in an earlier survey and now were at least 7 years postdiagnosis. Information was obtained regarding PTSD symptoms, positive and negative perceptions of the cancer experience (ie, impact of cancer), and other potential correlates of PTSD. RESULTS: A total of 566 individuals participated (83% response rate) with a median of 12.9 years since diagnosis; respondents were 52% female and 87% white. Although half (51%) of the respondents reported no PTSD symptoms and 12% reported a resolution of symptoms, more than one-third (37%) reported persistence or worsening of symptoms over 5 years. Survivors who reported a low income, stage ≥ 2 at diagnosis, aggressive lymphoma, having received chemotherapy, and greater impact of cancer (both positive and negative) at the initial survey had more PTSD symptoms at follow-up. In multivariable analysis, income and negative impacts of cancer were independent predictors of PTSD symptoms. CONCLUSION: More than one-third of long-term NHL survivors experience persisting or worsening PTSD symptoms. Providers should be aware of enduring risk; early identification of those at prolonged risk with standardized measures and treatments that target perceptions of the cancer experience might improve long-term outcomes.
PURPOSE: Little is known about the trajectory of post-traumatic stress disorder (PTSD) symptoms in cancer survivors, despite the fact that such knowledge can guide treatment. Therefore, this study examined changes in PTSD symptoms among long-term survivors of non-Hodgkin's lymphoma (NHL) and identified demographic, clinical, and psychosocial predictors and correlates of PTSD symptomatology. PATIENTS AND METHODS: Surveys were mailed to 682 NHL survivors who participated in an earlier survey and now were at least 7 years postdiagnosis. Information was obtained regarding PTSD symptoms, positive and negative perceptions of the cancer experience (ie, impact of cancer), and other potential correlates of PTSD. RESULTS: A total of 566 individuals participated (83% response rate) with a median of 12.9 years since diagnosis; respondents were 52% female and 87% white. Although half (51%) of the respondents reported no PTSD symptoms and 12% reported a resolution of symptoms, more than one-third (37%) reported persistence or worsening of symptoms over 5 years. Survivors who reported a low income, stage ≥ 2 at diagnosis, aggressive lymphoma, having received chemotherapy, and greater impact of cancer (both positive and negative) at the initial survey had more PTSD symptoms at follow-up. In multivariable analysis, income and negative impacts of cancer were independent predictors of PTSD symptoms. CONCLUSION: More than one-third of long-term NHL survivors experience persisting or worsening PTSD symptoms. Providers should be aware of enduring risk; early identification of those at prolonged risk with standardized measures and treatments that target perceptions of the cancer experience might improve long-term outcomes.
Authors: R K Pitman; D M Lanes; S K Williston; J L Guillaume; L J Metzger; G M Gehr; S P Orr Journal: Psychosomatics Date: 2001 Mar-Apr Impact factor: 2.386
Authors: Alice B Kornblith; James E Herndon; Raymond B Weiss; Chunfeng Zhang; Enid L Zuckerman; Sylvia Rosenberg; Magriet Mertz; David Payne; Mary Jane Massie; James F Holland; Patti Wingate; Larry Norton; Jimmie C Holland Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Catherine M Crespi; Sophia K Smith; Laura Petersen; Sheryl Zimmerman; Patricia A Ganz Journal: J Cancer Surviv Date: 2009-12-06 Impact factor: 4.442
Authors: Alv A Dahl; Marie Østby-Deglum; Jan Oldenburg; Roy Bremnes; Olav Dahl; Olbjørn Klepp; Erik Wist; Sophie D Fosså Journal: J Cancer Surviv Date: 2016-02-26 Impact factor: 4.442
Authors: Crystal S Denlinger; Robert W Carlson; Madhuri Are; K Scott Baker; Elizabeth Davis; Stephen B Edge; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Elizabeth Kvale; Terry S Langbaum; Jennifer A Ligibel; Mary S McCabe; Kevin T McVary; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Tracey O'Connor; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2014-01 Impact factor: 11.908
Authors: Laura P Forsythe; Neeraj K Arora; Catherine M Alfano; Kathryn E Weaver; Ann S Hamilton; Noreen Aziz; Julia H Rowland Journal: Support Care Cancer Date: 2014-01-12 Impact factor: 3.603
Authors: Shah-Jalal Sarker; Sophia K Smith; Kashfia Chowdhury; Patricia A Ganz; Sheryl Zimmerman; John Gribben; Ania Korszun Journal: Support Care Cancer Date: 2016-11-08 Impact factor: 3.603
Authors: Jessica Liang; Stephanie J Lee; Barry E Storer; Bronwen E Shaw; Eric J Chow; Mary E Flowers; Elizabeth F Krakow; Merav Bar; Karen L Syrjala; Rachel B Salit; Chareeni E Kurukulasuriya; Heather S L Jim Journal: Biol Blood Marrow Transplant Date: 2018-08-09 Impact factor: 5.742
Authors: Ellen Burke Beckjord; Kerry A Reynolds; G J van Londen; Rachel Burns; Reema Singh; Sarah R Arvey; Stephanie A Nutt; Ruth Rechis Journal: J Psychosoc Oncol Date: 2014